GLAXO WELLCOME MFG PTE LTD has a total of 95 patent applications. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization), United Kingdom and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and micro-structure and nano-technology are HONIGBERG LEE, CAVALLA DAVID and TIANJIN TIANSHILI PHARMACEUTIC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 19 | |
#2 | United Kingdom | 10 | |
#3 | China | 7 | |
#4 | Brazil | 5 | |
#5 | Canada | 5 | |
#6 | EPO (European Patent Office) | 5 | |
#7 | Mexico | 5 | |
#8 | Republic of Korea | 4 | |
#9 | Uruguay | 4 | |
#10 | Argentina | 3 | |
#11 | Israel | 3 | |
#12 | Singapore | 3 | |
#13 | Taiwan | 3 | |
#14 | United States | 3 | |
#15 | Australia | 2 | |
#16 | Colombia | 2 | |
#17 | Dominican Republic | 2 | |
#18 | Morocco | 2 | |
#19 | Peru | 2 | |
#20 | Chile | 1 | |
#21 | Costa Rica | 1 | |
#22 | EAPO (Eurasian Patent Organization) | 1 | |
#23 | New Zealand | 1 | |
#24 | Serbia | 1 | |
#25 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Micro-structure and nano-technology | |
#4 | Biotechnology | |
#5 | Measurement | |
#6 | Medical technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Nanostructure applications | |
#5 | Peptides | |
#6 | Measuring microorganism processes | |
#7 | Analysing materials | |
#8 | Syringes | |
#9 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Mclaughlin Megan M | 21 |
#2 | Alvaro Giuseppe | 17 |
#3 | Marasco Agostino | 16 |
#4 | Gupta Manish K | 16 |
#5 | Suttle Albert B | 11 |
#6 | Castiglioni Emiliano | 10 |
#7 | Damian-Iordache Valeriu | 9 |
#8 | Xu Chun-Fang | 9 |
#9 | King Andrew | 9 |
#10 | Wurzelmann John Irving | 8 |
Publication | Filing date | Title |
---|---|---|
WO2013066616A1 | Pazopanib formulation | |
US2013023550A1 | Pharmaceutical compositions and methods of making same | |
WO2012170752A1 | Novel compounds | |
WO2012103060A1 | Method of administration and treatment | |
WO2012083145A1 | Glucosamine derivatives | |
WO2012062835A1 | Novel pharmaceutical compositions | |
WO2011146458A1 | Method of administration and treatment | |
TW201206908A | Pharmaceutical compositions and methods of making same | |
TW201201808A | Treatment method | |
EP2490536A1 | Compositions and processes | |
WO2011038575A1 | Novel antibody treatment | |
WO2011039648A1 | Methods of administration and treatment | |
EP2453748A1 | Treatment method | |
TW201018482A | Novel treatment | |
GB0910687D0 | Novel compounds | |
GB0910680D0 | Novel compounds | |
GB0910667D0 | Novel compounds | |
GB0910689D0 | Novel compounds | |
GB0819609D0 | Novel compounds | |
GB0812849D0 | Novel compounds |